Mark Cuban is trying to shake up biosimilar pricing with a version of J&J’s best-selling Stelara drug By selling at a low price, Cuban hopes to convince health plans, employers to embrace his approach

https://www.statnews.com/pharmalot/2025/11/06/mark-cuban-biosimilar-jnj-stelara/